EXCELLENCE NESSUAH UPS TEVA PRICE TARGET
Excellence Nessuah has raised its price target for Israeli generic pharmaceuticals
company Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA ; TASE: TEVA) to $48.
This compares with a current market price of $40.17, at which Teva has a market
cap of $25.11 billion. Analyst Richard Gussow says that the recently-completed
$8.8 billion acquisition of Miami-based Ivax will further strengthen Teva's
already advantageous position in a market about to enjoy something of a boom,
with a high number of drug patents close to expiry, and yet Teva is not traded
at a premium.